Research Analysts Offer Predictions for UroGen Pharma’s Q2 2018 Earnings (URGN)

UroGen Pharma (NASDAQ:URGN) – Research analysts at Oppenheimer issued their Q2 2018 earnings estimates for UroGen Pharma in a report issued on Tuesday, May 15th. Oppenheimer analyst L. Gershell expects that the company will post earnings per share of ($1.00) for the quarter. Oppenheimer has a “Buy” rating and a $75.00 price objective on the stock. Oppenheimer also issued estimates for UroGen Pharma’s Q3 2018 earnings at ($1.01) EPS, Q4 2018 earnings at ($1.03) EPS, FY2018 earnings at ($3.92) EPS, FY2019 earnings at ($4.27) EPS, FY2020 earnings at $0.57 EPS, FY2021 earnings at $4.42 EPS and FY2022 earnings at $9.47 EPS.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Tuesday, May 15th. The company reported ($0.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.15). The business had revenue of $0.48 million during the quarter.

Several other equities analysts have also weighed in on URGN. Ladenburg Thalmann restated a “buy” rating and set a $65.00 target price on shares of UroGen Pharma in a report on Friday, March 16th. Jefferies Group restated a “buy” rating on shares of UroGen Pharma in a report on Monday, March 19th. Raymond James upgraded UroGen Pharma from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 4th. UBS upgraded UroGen Pharma from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 4th. Finally, ValuEngine upgraded UroGen Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. UroGen Pharma currently has a consensus rating of “Buy” and a consensus target price of $45.50.

NASDAQ URGN opened at $62.04 on Friday. UroGen Pharma has a fifty-two week low of $61.05 and a fifty-two week high of $61.50.

Several large investors have recently modified their holdings of URGN. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of UroGen Pharma in the fourth quarter valued at about $166,000. JPMorgan Chase & Co. acquired a new stake in shares of UroGen Pharma in the third quarter valued at about $168,000. Quantbot Technologies LP acquired a new stake in shares of UroGen Pharma in the first quarter valued at about $174,000. UBS Group AG grew its position in shares of UroGen Pharma by 31.5% in the first quarter. UBS Group AG now owns 3,611 shares of the company’s stock valued at $180,000 after purchasing an additional 865 shares during the last quarter. Finally, MYDA Advisors LLC acquired a new stake in shares of UroGen Pharma in the fourth quarter valued at about $223,000. 53.00% of the stock is currently owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply